|
Market Closed -
Nasdaq
01:16:00 13/01/2026 +03
|
5-day change
|
1st Jan Change
|
|
23,733.90 PTS
|
+0.26%
|
|
+1.45%
|
+2.12%
|
| 03:01pm |
Deutsche Bank Adjusts Price Target on Nasdaq to $116 From $111, Maintains Buy Rating
|
MT
| | 02:58pm |
Kolibri Global Energy Provides Operations Update on Tishomingo Field Wells
|
MT
| | 02:58pm |
Morgan Stanley Adjusts Price Target on eBay to $112 From $102, Maintains Overweight Rating
|
MT
| | 02:57pm |
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Rocket Lab to Advance, Microsoft to Decline
|
MT
| | 02:55pm |
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating
|
MT
| | 02:55pm |
Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating
|
MT
| | 02:37pm |
Baidu CFO on Business Strategy, AI Investments
|
MT
| | 02:14pm |
TD Cowen Adjusts Price Target on Meta Platforms to $820 From $810, Maintains Buy Rating
|
MT
| | 02:09pm |
Kolibri Global Energy Brief: Provided Operations Update On Its Latest Wells In Its Tishomingo Field in Oklahoma
|
MT
| | 02:08pm |
Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec
|
RE
| | 02:06pm |
Amgen's Extension Study Shows MariTide Helped Maintain Weight Loss at Lower Dose, Less Frequency
|
MT
| | 01:53pm |
Canada's OpenText Opens Regional Headquarters in Saudi Arabia
|
MT
| | 01:49pm |
KeyBanc Upgrades Intel to Overweight From Sector Weight, Price Target is $60
|
MT
| | 01:49pm |
Piper Sandler Downgrades Synopsys to Neutral From Overweight, Adjusts PT to $520 From $602
|
MT
| | 01:13pm |
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down
|
MT
| | 01:11pm |
Alnylam Pharmaceuticals CEO on Development Goals, Profitability
|
MT
| | 12:51pm |
Microsoft to Modify Data Center Power Use Following Trump Agreement
|
MT
| | 12:41pm |
Oak Valley Bancorp Names Bill Nunes as Chief Marketing Officer
|
MT
| | 12:31pm |
Apple, Google strike Gemini deal for revamped Siri
|
RE
| | 11:50am |
Forvia Hella announces strategic development with Analog Devices
|
RE
| | 11:35am |
Kratos Defense & Security Solutions Insider Sold Shares Worth $2,355,667, According to a Recent SEC Filing
|
MT
| | 10:35am |
CME changes margin-setting methodology for precious metals
|
RE
| | 08:50am |
Press digest - New York Times business news - January 13
|
RE
| | 03:41am |
Amgen says MariTide helped trial patients maintain weight loss
|
RE
| | 03:11am |
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
|
RE
| | 02:59am |
Trump says Microsoft to make changes to curb data center power costs for Americans
|
RE
| | 02:54am |
Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed
|
RE
| | 02:54am |
Amgen: "Large majority" of people in 52-week Maritide extension study given lower monthly dose or quarterly dose of drug maintained weight loss achieved in part 1 of phase 2 trial
|
RE
| | 02:50am |
Amgen says 24-week study of monthly Maritide in people with type 2 diabetes showed robust, clinically meaningful reduction in both HbA1c, weight
|
RE
| | 02:46am |
Amgen to announce data on obesity drug MariTide at healthcare conference
|
RE
| | 02:15am |
Medallion Bank - promotes Travis Betenson to SVP and CFO
|
RE
| |
01-13 |
Microsoft-Backed OpenAI Agrees to Buy Health AI Startup Torch in $100 Million Deal
|
MT
| |
01-13 |
Tech Up on AI Views -- Tech Roundup
|
DJ
| |
01-13 |
Meta to Cut 10% Jobs in Reality Labs
|
MT
| |
01-13 |
Cadence Design Systems Insider Sold Shares Worth $2,009,189, According to a Recent SEC Filing
|
MT
| |
01-13 |
MercadoLibre lays off 119 people due to its AI expansion, Folha reports
|
RE
| |
01-13 |
Matthews International to Redeem Senior Secured Notes due 2027
|
MT
| |
01-13 |
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FY - SEC filing
|
RE
| |
01-13 |
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer
|
MT
| |
01-13 |
Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience
|
MT
|
No results for this search
Highest NASDAQ Composite increases
|
|
|
|
+36,566.67%
|
|
|
+9,900.00%
|
|
|
+9,900.00%
|
|
|
+9,900.00%
|
|
|
+9,900.00%
|
The sharpest declines in NASDAQ Composite.
|
|
|
|
-99.00%
|
|
|
-99.00%
|
|
|
-99.00%
|
|
|
-99.50%
|
|
|
-99.80%
|
See the ranking
Detailed heatmap
Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
|